Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Phytomedicine ; 127: 155503, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38490077

RESUMEN

BACKGROUND: Natural products have demonstrated significant potential in cancer drug discovery, particularly in renal cancer (RCa), urothelial carcinoma (UC), and testicular cancer (TC). PURPOSE: This review aims to examine the effects of natural products on RCa, UC and TC. STUDY DESIGN: systematic review METHODS: PubMed and Web of Science databases were retrieved to search studies about the effects of natural products and derivatives on these cancers. Relevant publications in the reference list of enrolled studies were also checked. RESULTS: This review highlighted their diverse impacts on key aspects such as cell growth, apoptosis, metastasis, therapy response, and the immune microenvironment. Natural products not only hold promise for novel drug development but also enhance the efficacy of existing chemotherapy and immunotherapy. Importantly, we exert their effects through modulation of critical pathways and target genes, including the PI3K/AKT pathway, NF-κB pathway, STAT pathway and MAPK pathway, among others in RCa, UC, and TC. CONCLUSION: These mechanistic insights provide valuable guidance for researchers, facilitating the selection of promising natural products for cancer management and offering potential avenues for further gene regulation studies in the context of cancer treatment.


Asunto(s)
Productos Biológicos , Carcinoma de Células Transicionales , Neoplasias de Células Germinales y Embrionarias , Neoplasias Testiculares , Neoplasias de la Vejiga Urinaria , Masculino , Humanos , Carcinoma de Células Transicionales/genética , Carcinoma de Células Transicionales/metabolismo , Carcinoma de Células Transicionales/patología , Neoplasias de la Vejiga Urinaria/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Neoplasias Testiculares/tratamiento farmacológico , Productos Biológicos/farmacología , Productos Biológicos/uso terapéutico , Transducción de Señal , Microambiente Tumoral
2.
Prostate ; 83(7): 722-728, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-36891865

RESUMEN

PURPOSE: The objective of this study is to analyze characteristics of recurrent acute urinary retention (AUR) in patients with benign prostatic hyperplasia (BPH), utilizing a population based data set. Also, we sought to report on how AUR was treated, specifically regarding the need and length of catheterization and types of procedures utilized for mitigation. MATERIALS & METHODS: A retrospective observational cohort study was performed using Optum's deidentified Clinformatics® Data Mart Database. We compared two groups, BPH patients with AUR (n = 180,737) and BPH patients without AUR (n = 1,139,760) from January 1, 2003 to December 31, 2017. Also, we analyzed the factors affecting the development of multiple episodes of AUR through age-adjusted multivariate analysis. RESULTS: In contrast to the 47.7% of patients who had a single AUR episode, 33.5% of AUR patients developed 3 or more subsequent episodes of retention. For age matched patients, the risks of additional episodes of retention increase significantly with older age, Caucasian race, diabetes, neurologic conditions, or low income. Overall, the rate of BPH surgery in AUR patients over the study period decreased and the most common procedure was transurethral resection of the prostate. CONCLUSIONS: Risk factors for multiple episodes of AUR included age (60 and older), Caucasian race, lower income socioeconomic status, diabetes, and neurological disorders. Patients with a high probability of developing recurrent episodes of AUR are recommended to receive preemptive BPH medication before such AUR occurrences. Also, more expeditious surgical treatment should be considered rather than temporary catheterization when AUR occurs.


Asunto(s)
Hiperplasia Prostática , Resección Transuretral de la Próstata , Retención Urinaria , Masculino , Humanos , Estados Unidos/epidemiología , Hiperplasia Prostática/complicaciones , Hiperplasia Prostática/epidemiología , Hiperplasia Prostática/tratamiento farmacológico , Retención Urinaria/epidemiología , Retención Urinaria/etiología , Estudios Retrospectivos , Resección Transuretral de la Próstata/efectos adversos , Factores de Riesgo , Enfermedad Aguda
3.
J Korean Med Sci ; 31(11): 1808-1813, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27709861

RESUMEN

The objectives of this study were to investigate risk factors and the incidence of ciprofloxacin resistance and extended-spectrum beta-lactamases (ESBL) in patients with acute bacterial prostatitis (ABP). We reviewed the medical records of 307 patients who were diagnosed with ABP between January 2006 and December 2015. The etiologic pathogens and risk factors for ciprofloxacin-resistant E. coli and ESBL-producing microbes, susceptibility to ciprofloxacin, and the incidence of ESBL in patients with ABP were described. History of prior urologic manipulation was an independent risk factor for ciprofloxacin-resistant (P = 0.005) and ESBL-producing microbes (P = 0.005). Advanced age (over 60 years) was an independent risk factor for ciprofloxacin-resistant microbes (P = 0.022). The ciprofloxacin susceptibility for Escherichia coli in groups without prior manipulation was documented 85.7%. For groups with prior manipulation, the susceptibility was 10.0%. Incidence of ESBL-producing microbes by pathogen was 3.8% for E. coli and 1.0% for Klebsiella pneumonia in the absence of manipulation group, and 20% and 33.3% in the presence of manipulation group, respectively. Initial treatment of ABP must consider patient's age and the possibility of prior manipulation to optimize patient treatment. With the high rate of resistance to fluoroquinolone, cephalosporins with amikacin, or carbapenems, or extended-spectrum penicillin with beta lactamase inhibitor should be considered as the preferred empirical ABP treatment in the patients with history of prior urologic manipulation.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Ciprofloxacina/uso terapéutico , Farmacorresistencia Bacteriana , Prostatitis/diagnóstico , beta-Lactamasas/metabolismo , Enfermedad Aguda , Adulto , Factores de Edad , Anciano , Amicacina/farmacología , Antibacterianos/farmacología , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/microbiología , Cefalosporinas/farmacología , Escherichia coli/efectos de los fármacos , Escherichia coli/enzimología , Escherichia coli/aislamiento & purificación , Humanos , Imipenem/farmacología , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/aislamiento & purificación , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , República de Corea , Estudios Retrospectivos , Factores de Riesgo
4.
J Sex Med ; 6(1): 251-6, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18624960

RESUMEN

INTRODUCTION: The recent human and animal studies indicate that the central supraspinal systems controlling penile erection, which are localized predominantly in the parts of the frontal lobe and limbic system, are reported to be involved in erection. AIM: The purpose of this study was to elucidate the correlation of the erectile dysfunction (ED) with lesions of cerebrovascular accidents (CVA). METHODS: Forty-four men were selected among the CVA patients who had visited our hospital between March and July 2006. The audiovisual sexual stimulation (AVSS) test was conducted using Rigiscan device on the patients, whose erectile domain score of the International Index of Erectile Function Questionnaire (IIEF) was less than 22. The criteria for adequate erectile function was the erectile events of > 60% rigidity for > or = 5 minutes. The CVA lesions were classified into frontal lobe, cortex except frontal lobe, basal ganglia, thalamus, and other area. Each CVA lesions of ED group and non-ED group were compared. MAIN OUTCOME MEASURE: IIEF, AVSS using Rigiscan. RESULT: Thirty-eight patients' erectile domain score of IIEF were less than 22, and the AVSS test was conducted on them. Eighteen patients showed no ED, and 20 patients showed ED. The mean age of the ED group was 60.40 +/- 2.2, and the mean age of non-ED group was 55.29 +/- 1.85. There was no statistically significant difference between the mean age of both groups (P = 0.081). As each CVA lesions of both groups were compared, the CVA lesions of the thalamic area in the ED group were significantly more than in the non-ED group (P = 0.010). CONCLUSIONS: Patients (47.4%) who were suggestive of ED in the IIEF has no ED in the AVSS test. The patients who had CVA lesions in the thalamic area more commonly showed ED than the patients with CVA lesions of any other areas.


Asunto(s)
Trastornos Cerebrovasculares/epidemiología , Disfunción Eréctil/diagnóstico , Disfunción Eréctil/epidemiología , Ganglios Basales/patología , Trastornos Cerebrovasculares/diagnóstico , Lóbulo Frontal/patología , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Tálamo/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA